Robin Isaacs

5.1k total citations · 2 hit papers
40 papers, 2.8k citations indexed

About

Robin Isaacs is a scholar working on Infectious Diseases, Pharmacology and Virology. According to data from OpenAlex, Robin Isaacs has authored 40 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 12 papers in Pharmacology and 11 papers in Virology. Recurrent topics in Robin Isaacs's work include Antibiotics Pharmacokinetics and Efficacy (12 papers), HIV/AIDS drug development and treatment (12 papers) and HIV Research and Treatment (11 papers). Robin Isaacs is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (12 papers), HIV/AIDS drug development and treatment (12 papers) and HIV Research and Treatment (11 papers). Robin Isaacs collaborates with scholars based in United States, New Zealand and Japan. Robin Isaacs's co-authors include Charles J. Gonzalez, Hedy Teppler, Bach‐Yen Nguyen, Charlotte M. Harvey, Larissa Wenning, Javier O Morales-Ramirez, Colin Kovacs, Christine Katlama, Daniel Vittecoq and Beatriz Grinsztejn and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Investigation.

In The Last Decade

Robin Isaacs

40 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

2007 453 citations Beatriz Grinsztejn, Christine Katlama et al. profile →
Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

2023 146 citations Keith S. Kaye, Andrew F. Shorr et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robin Isaacs United States	25	1.9k	1.5k	469	454	392	40	2.8k
B. Marchou France	35	2.3k 1.2×	1.5k 1.0×	429 0.9×	1.2k 2.7×	197 0.5×	144	3.8k
Helmut Albrecht United States	31	1.4k 0.8×	865 0.6×	250 0.5×	1.0k 2.2×	197 0.5×	121	3.1k
Ploenchan Chetchotisakd Thailand	32	2.3k 1.2×	1.0k 0.7×	160 0.3×	2.1k 4.7×	212 0.5×	117	3.8k
Bruce L. Gilliam United States	21	744 0.4×	498 0.3×	101 0.2×	540 1.2×	157 0.4×	62	1.5k
G. P. Melcher United States	24	1.1k 0.6×	763 0.5×	242 0.5×	769 1.7×	40 0.1×	38	2.1k
Richard Hafner United States	40	3.4k 1.8×	446 0.3×	491 1.0×	3.7k 8.1×	129 0.3×	86	5.2k
Laurent Hocqueloux France	25	1.7k 0.9×	1.4k 0.9×	204 0.4×	662 1.5×	26 0.1×	94	2.7k
Patrice Massip France	40	2.5k 1.3×	2.3k 1.5×	280 0.6×	1.0k 2.2×	23 0.1×	127	4.0k
Johan N. Bruun Norway	22	1.1k 0.6×	773 0.5×	170 0.4×	692 1.5×	40 0.1×	75	2.3k
Katia Boggian Switzerland	21	1.4k 0.7×	456 0.3×	132 0.3×	1.4k 3.0×	63 0.2×	58	2.4k

Countries citing papers authored by Robin Isaacs

Since Specialization

Citations

This map shows the geographic impact of Robin Isaacs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Isaacs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Isaacs more than expected).

Fields of papers citing papers by Robin Isaacs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Isaacs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Isaacs. The network helps show where Robin Isaacs may publish in the future.

Co-authorship network of co-authors of Robin Isaacs

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Isaacs. A scholar is included among the top collaborators of Robin Isaacs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Isaacs. Robin Isaacs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kaye, Keith S., Andrew F. Shorr, Richard G. Wunderink, et al.. (2023). Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). The Lancet Infectious Diseases. 23(9). 1072–1084. 146 indexed citations breakdown →

Watkins, Richard, Bin Du, Robin Isaacs, & David Altarac. (2023). Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial. Clinical Infectious Diseases. 76(Supplement_2). S210–S214. 5 indexed citations

Lickliter, Jason D., Kenneth Lawrence, John P. O’Donnell, & Robin Isaacs. (2017). Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β-lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β-lactamases. Open Forum Infectious Diseases. 4(suppl_1). S524–S524. 8 indexed citations

Patnaik, Amita, Glen J. Weiss, K. Papadopoulos, et al.. (2014). Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. British Journal of Cancer. 111(2). 272–280. 37 indexed citations

Nguyen, Bach‐Yen, Robin Isaacs, Hedy Teppler, et al.. (2011). Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium. Annals of the New York Academy of Sciences. 1222(1). 83–89. 41 indexed citations

Gatell, José M., Christine Katlama, Beatriz Grinsztejn, et al.. (2010). Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 53(4). 456–463. 53 indexed citations

Markowitz, Martin, Bach‐Yen Nguyen, Eduardo Gotuzzo, et al.. (2009). Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 52(3). 350–356. 94 indexed citations

Iwamoto, Marian, Larissa Wenning, Bach‐Yen Nguyen, et al.. (2009). Effects of Omeprazole on Plasma Levels of Raltegravir. Clinical Infectious Diseases. 48(4). 489–492. 69 indexed citations

Markowitz, Martin, Javier O Morales-Ramirez, Bach‐Yen Nguyen, et al.. (2006). Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(5). 509–515. 293 indexed citations

10.

Woods, Gail L., Robin Isaacs, Kathleen McCarroll, & Ian R. Friedland. (2003). Ertapenem Therapy for Community‐Acquired Pneumonia in the Elderly. Journal of the American Geriatrics Society. 51(11). 1526–1532. 19 indexed citations

11.

Gulick, Roy M., Anne R. Meibohm, Diane V. Havlir, et al.. (2003). Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS. 17(16). 2345–2349. 50 indexed citations

12.

Friedland, Ian R., Robin Isaacs, Lori Mixson, Mary Motyl, & Gail L. Woods. (2002). Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagnostic Microbiology and Infectious Disease. 43(1). 61–64. 16 indexed citations

13.

Günthard, Huldrych F., Diane V. Havlir, Susan A. Fiscus, et al.. (2001). Residual Human Immunodeficiency Virus (HIV) Type 1 RNA and DNA in Lymph Nodes and HIV RNA in Genital Secretions and in Cerebrospinal Fluid after Suppression of Viremia for 2 Years. The Journal of Infectious Diseases. 183(9). 1318–1327. 122 indexed citations

14.

Isaacs, Robin. (1994). Borrelia burgdorferi bind to epithelial cell proteoglycans.. Journal of Clinical Investigation. 93(2). 809–819. 94 indexed citations

15.

Rose, Thierry, D. A. Bremner, James F. Collins, et al.. (1990). Plasma and dialysate levels of pefloxacin and its metabolites in CAPD patients with peritonitis. Journal of Antimicrobial Chemotherapy. 25(4). 657–664. 5 indexed citations

16.

Isaacs, Robin, et al.. (1988). SHORT COURSE CHEMOTHERAPY FOR MENINGOCOCCAL MENINGITIS. Australian and New Zealand Journal of Medicine. 18(5). 731–732. 2 indexed citations

17.

Isaacs, Robin, et al.. (1988). Wound infection with aerogenicAeromonas strains: A review of twenty-seven cases. European Journal of Clinical Microbiology & Infectious Diseases. 7(3). 355–360. 23 indexed citations

18.

Isaacs, Robin, Nicholas J. Beeching, & R. B. Ellis‐Pegler. (1987). Cystic hydatid disease in Auckland, New Zealand, 1967–1982. Transactions of the Royal Society of Tropical Medicine and Hygiene. 81(5). 794–798. 6 indexed citations

19.

Isaacs, Robin & R. B. Ellis‐Pegler. (1987). Successful treatment of Morganella morganii meningitis with pefloxacin mesylate. Journal of Antimicrobial Chemotherapy. 20(5). 769–770. 6 indexed citations

20.

Isaacs, Robin. (1986). Necrotizing pneumonia in bacteraemic pneumococcal infection. British Journal of Diseases of the Chest. 80(3). 295–296. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact